Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
Radnor, Pa. — January 29, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraJanuary 29, 2026
Regulatory-Trusted Software for Smarter PK/PD Workflows (Phoenix WinNonlin®)
This on demand session demonstrates how Phoenix WinNonlin® and other tools work together within Phoenix®…
CertaraJanuary 27, 2026
How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
CertaraJanuary 26, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…
CertaraJanuary 22, 2026
